Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study by van Dooren, Fleur E P et al.
Syddansk Universitet
Associations of low grade inflammation and endothelial dysfunction with depression -
The Maastricht Study
van Dooren, Fleur E P; Schram, Miranda T; Schalkwijk, Casper G; Stehouwer, Coen D A;
Henry, Ronald M A; Dagnelie, Pieter C; Schaper, Nicolaas C; van der Kallen, Carla J H;
Koster, Annemarie; Sep, Simone J S; Denollet, Johan; Verhey, Frans R J; Pouwer, Francois
Published in:
Brain, Behavior, and Immunity
DOI:
10.1016/j.bbi.2016.03.004
Publication date:
2016
Document version
Peer reviewed version
Document license
CC BY-NC-ND
Citation for pulished version (APA):
van Dooren, F. E. P., Schram, M. T., Schalkwijk, C. G., Stehouwer, C. D. A., Henry, R. M. A., Dagnelie, P. C., ...
Pouwer, F. (2016). Associations of low grade inflammation and endothelial dysfunction with depression - The
Maastricht Study. Brain, Behavior, and Immunity, 56(August), 390-6. DOI: 10.1016/j.bbi.2016.03.004
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
Accepted Manuscript
Associations of low grade inflammation and endothelial dysfunction with de-
pression - The Maastricht Study
Fleur E.P. van Dooren, Miranda T. Schram, Casper G. Schalkwijk, Coen D.A.
Stehouwer, Ronald M.A. Henry, Pieter C. Dagnelie, Nicolaas C. Schaper, Carla
J.H. van der Kallen, Annemarie Koster, Simone J.S. Sep, Johan Denollet, Frans
R.J. Verhey, Frans Pouwer
PII: S0889-1591(16)30049-6
DOI: http://dx.doi.org/10.1016/j.bbi.2016.03.004
Reference: YBRBI 2824
To appear in: Brain, Behavior, and Immunity
Received Date: 30 December 2015
Revised Date: 29 February 2016
Accepted Date: 8 March 2016
Please cite this article as: van Dooren, F.E.P., Schram, M.T., Schalkwijk, C.G., Stehouwer, C.D.A., Henry, R.M.A.,
Dagnelie, P.C., Schaper, N.C., van der Kallen, C.J.H., Koster, A., Sep, S.J.S., Denollet, J., Verhey, F.R.J., Pouwer,
F., Associations of low grade inflammation and endothelial dysfunction with depression - The Maastricht Study,
Brain, Behavior, and Immunity (2016), doi: http://dx.doi.org/10.1016/j.bbi.2016.03.004
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1 
 
Title: Associations of low grade inflammation and endothelial dysfunction with depression - 
The Maastricht Study 
 
Authors: Fleur E.P. van Dooren, M.Sc.
1,3,4
;  Miranda T. Schram, Ph.D.
1,2
; Casper G. Schalkwijk, 
Ph.D.1,2; Coen D.A. Stehouwer, Ph.D.1,2; Ronald M.A. Henry, Ph.D.1,2; Pieter C. Dagnelie, 
Ph.D.
2,6,7
; Nicolaas C. Schaper, Ph.D.
1,2,6
; Carla J.H. van der Kallen, Ph.D.
1,2
; Annemarie Koster, 
Ph.D.
5,6
; Simone J.S. Sep, Ph.D.
1,2
; Johan Denollet, Ph.D.
3
; Frans R.J. Verhey, Ph.D.
4
; Frans 
Pouwer, Ph.D.3 
 
1 
Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, the 
Netherlands, 2 CARIM Cardiovascular Research Institute Maastricht, Maastricht University, 
Maastricht, the Netherlands, 
3
 CoRPS – Center of Research on Psychology in Somatic 
diseases, Department of Medical and Clinical Psychology, Tilburg University, Tilburg, The 
Netherlands, 4 MHeNS – Alzheimer Centre Limburg, School for Mental Health and 
Neuroscience, Maastricht University, Maastricht, The Netherlands, 
5 
Department of Social 
Medicine, Maastricht University, Maastricht, the Netherlands, 
6
 CAPHRI School for Public 
Health and Primary Care, Maastricht University, Maastricht, the Netherlands, 7 Department 
of Epidemiology, Maastricht University, Maastricht, the Netherlands 
 
All correspondence to: Fleur E.P. van Dooren, M.Sc, Maastricht UMC+,  Dept. Medicine, p/a 
De Maastricht Studie, Randwycksingel 35, 6229 EG  Maastricht, The Netherlands 
Email: F.E.P.vanDooren@uvt.nl Phone: + 31- 43 387 1104 
 
  
  
2 
 
Abstract 
 
Background:  The pathogenesis of depression may involve low-grade inflammation and 
endothelial dysfunction. We aimed to evaluate the independent associations of 
inflammation and endothelial dysfunction with depressive symptoms and depressive 
disorder, and the role of lifestyle factors in this association.  
 
Methods:  In The Maastricht Study, a population-based cohort study (n=852, 55% men, 
m=59.8±8.5 years), depressive symptoms were assessed with the Patient Health 
Questionnaire-9 and (major and minor) depressive disorder with the Mini-International 
Neuropsychiatric Interview. Plasma biomarkers of inflammation (hsCRP, SAA, sICAM-1, IL-6, 
IL-8, TNF-α) and endothelial dysfunction (sVCAM-1, sICAM-1, sE-selectin, vWF) were 
measured with sandwich immunoassays and combined into two standardized sum scores.  
 
Results: Biomarkers of inflammation (hsCRP, TNF-α, SAA, sICAM-1) and endothelial 
dysfunction (sICAM-1, sE-Selectin) were univariately associated with depressive symptoms 
and depressive disorder. The sum scores of inflammation and endothelial dysfunction were 
associated with depressive disorder after adjustment for age, sex, type 2 diabetes, kidney 
function and prior cardiovascular disease (OR 1.54, p=0.001 and 1.40, p=0.006). Both sum 
scores remained significantly associated with depressive disorder after additional 
adjustment for lifestyle factors smoking, alcohol consumption and body mass index. The sum 
score of inflammation was also independently associated with depressive symptoms, while 
the sum score of endothelial dysfunction was not.  
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Conclusions: Inflammation and endothelial dysfunction are both associated with depressive 
disorder, independent of lifestyle factors. Our results might suggest that inflammation and 
endothelial dysfunction are involved indepression.  
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Introduction 
Depression is a complex disorder with a highly variable course, an inconsistent response to 
treatment, and no established mechanism. Its development is probably characterized by the 
interaction between biological, genetic and environmental factors (Oladeji and Gureje, 
2013). Apart from the detrimental impact of depression on the quality of life of individuals 
affected with the disorder and their family members, depression is also related to high 
societal costs as a consequence of diminished work productivity and increased use of health 
care (Greenberg et al., 2015). According to the World Health Organization (WHO), 
depression is the leading cause of disability worldwide, and is a major contributor to the 
overall global burden of disease as measured by Disability Adjusted Lived Years (WHO, 
2015), therefore making the identification of its etiology a research priority.  
Increasing evidence suggests that inflammatory pathways may play a role in the 
development of depression (Valkanova et al., 2013), with elevated oxidative stress, (Maes et 
al., 2011; Riemer et al., 2010) and psychosocial stressors (Moylan et al., 2013) as proposed 
mechanisms. For example, psychosocial stressors, including acute psychological trauma or 
early exposure to childhood trauma, strongly increase the risk of developing clinical 
depression and mood symptoms, while impacting neuroimmune circuits (Berk et al., 2013). 
There is evidence that different types of psychosocial stressors may stimulate the pro-
inflammatory cytokine network, including increases in IL-6 and TNFα (Maes et al., 1998), and 
subsequently could lead to the development of depression. Moreover, previous research has 
shown that treatment with the anti-inflammatory drug infliximab significantly decreased 
depressive symptoms in patients with increased CRP, but not in depressed patients without 
raised inflammatory markers (Raison et al., 2013). In addition, a recent meta-analysis based 
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on 14 trials (Kohler et al., 2014) showed that anti-inflammatory treatment, in particular 
celecoxib, decreased depressive symptoms without increased risks of adverse effects. 
Both inflammation and oxidative stress are strongly linked to the development of 
endothelial dysfunction. Several studies indeed report an association of endothelial 
dysfunction with depression (Hemingway et al., 2003; Lesperance et al., 2004; van Sloten et 
al., 2014). However, large scale studies on the interrelation between inflammation and 
endothelial dysfunction in their association with depression remain scarce, whereas these 
processes are biologically interrelated and may therefore be interdependent (Stehouwer et 
al., 2002). In addition, most studies on endothelial dysfunction and depression yielded 
inconsistent results, some showing significant positive associations between endothelial 
dysfunction and depression (Sherwood et al., 2005), whereas others showed no association 
(Do et al., 2010). This is possibly due to the methods used to assess endothelial dysfunction 
or depression, i.e. only a few studies have used a diagnostic interview, the gold standard to 
assess depressive disorder.  
In view of the above, we aimed to evaluate whether inflammation and endothelial 
dysfunction, as measured with a wide variety of biomarkers, are positively associated with 
depressive symptoms and depressive disorder as assessed with a self-report questionnaire 
and a diagnostic interview, respectively. Furthermore, we aimed to evaluate whether these 
associations are independent of the possible confounders age, sex,  type 2 diabetes, 
estimated glomerular filtration rate and prior cardiovascular disease. In addition, we also 
aimed to evaluate the possible role of several life style factors in this association.   
 
Materials and Methods 
Study population 
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In this study, we used data from The Maastricht Study, an observational prospective 
population-based cohort study. The rationale and methodology have been described 
previously (Schram et al., 2014). In brief, the study focuses on the etiology, pathophysiology, 
complications and comorbidities of type 2 diabetes mellitus and is characterized by an 
extensive phenotyping approach. Extensive assessments of both depressive symptoms and 
depressive disorder were part of the protocol. Eligible for participation were all individuals 
aged between 40 and 75 years and living in the southern part of the Netherlands. 
Participants were recruited through mass media campaigns and from the municipal 
registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified 
according to known type 2 diabetes status, with an oversampling of individuals with type 2 
diabetes, for reasons of efficiency. The present report includes cross-sectional data from the 
first 852 participants, who completed the baseline survey between November 2010 and 
March 2012. The examinations of each participant were performed within a time window of 
three months, and all measurements were performed in The Maastricht Study research 
center using standardized protocols. The study has been approved by the institutional 
medical ethical committee (NL31329.068.10) and the Netherlands Health Council under the 
Dutch “Law for Population Studies” (Permit 131088-105234-PG). All participants gave 
written informed consent.  
 
Markers of low-grade inflammation (LGI) and endothelial dysfunction (ED)  
Plasma biomarkers of LGI (high sensitivity C-reactive protein (CRP), serum amyloid A (SAA), 
soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-6 (IL-6), interleukin-8 (IL-8) 
and tumor necrosis factor alpha (TNF-α)) were measured in EDTA plasma samples with 
commercially available 4-plex sandwich immunoassay kits (Meso Scale Discovery (MSD), 
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Rockville, MD, US). For this study, the intra- and inter-assay coefficients of variation were 
3.0% and 4.7% for CRP, 2.6% and 7.5% for SAA, 2.5% and 5.3% for sICAM-1, 7.2% and 12.7% 
for IL-6, 3.1% and 5.6% for IL-8, and 4.3% and 7.5% for TNF-α, respectively. Of the plasma 
biomarkers of ED (soluble vascular cell adhesion molecule-1 (sVCAM-1), sICAM-1, soluble E-
selectin (sE-selectin) and Von Willebrand factor (vWF)), sVCAM-1, sICAM-1, and sE-selectin 
were measurered in EDTA plasma samples with commercially available 4-plex sandwich 
immunoassay kits (Meso Scale Discovery (MSD), Rockville, MD, US). vWf was determined in 
citrated plasma with sandwich ELISA (Dako, Glostrup, Denmark). Concentrations of vWf were 
expressed as a percentage of vWf detected in pooled citrated plasma of healthy volunteers. 
For the present study, the intra- and inter-assay coefficients of variation were 3.5% and 5.9% 
for sVCAM-1 , 2.5% and 5.3% for sICAM-1, 6.4% and 6.0% for sE-selectin, and 3.2% and 5.4% 
for vWF.  
 
Assessment of depression 
Depressive symptoms in the preceding two weeks were assessed by a validated Dutch 
version of the 9-item Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001). The PHQ-
9 is a self-administered questionnaire based on the DMS-IV (APA, 1994) criteria for a major 
depressive disorder. It comprises nine items rated on a four-point scale, ranging from 0 = 
“not at all” to 3 = “nearly every day”. Response options are used to calculate a continuous 
total-score ranging from 0 (no symptoms) to 27 (all symptoms present nearly every day). 
Depressive disorder was assessed by the Mini-International Neuropsychiatric Interview 
(MINI) (Sheehan et al., 1998). The MINI is a short diagnostic structured interview, used to 
assess the presence of current minor or major depressive disorder in the preceding 2 weeks 
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according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition).  
Data collection 
Partner status, diabetes duration, smoking behavior, alcohol consumption, physical activity 
and history of cardiovascular disease (CVD) were assessed by means of a self-report 
questionnaire (Schram et al., 2014). Fasting venous blood samples were used to assess 
glucose levels, HbA1c and lipid profile. Medication use was assessed by interview. Office 
blood pressure was measured three times on the right arm after 10 minutes of seated rest, 
the mean of these three measurements was used for analyses.  
To determine diabetes status, all participants (except those who use insulin) underwent a 
standardized 7-point 75g oral glucose tolerance test (OGTT) after an overnight fast as 
previously described (Schram et al., 2014). Individuals without type 1 diabetes (T1DM) and 
on diabetes medication were considered to have T2DM (Schram et al., 2014). Weight, 
height, waist and hip circumference were measured, subsequently body mass index (BMI) 
and waist-to-hip ratio were calculated. Glomerular filtration rate (eGFR) was estimated 
according to the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, 
based on serum creatinine (Levey et al., 2009).  
 
Statistical analyses 
All analyses were performed using SPSS version 19 for MS-Windows (SPSS, Inc.). Baseline 
characteristics of individuals with versus without depressive disorder were compared using 
Independent Samples T-tests, Mann-Whitney U test and Chi-square tests, where 
appropriate. All variables with a skewed distribution were log-transformed before regression 
analyses. For reasons of statistical efficiency and to reduce the influence of the biological 
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variability of each measure, a standardized sum score was determined for both LGI and ED, 
according to predefined clusters of conceptually related biomarkers (de Jager et al., 2006; 
Yudkin et al., 1999). Before creating the sum scores, variables with a skewed distribution 
were log-transformed. The standardized sum scores were calculated as follows: for each 
individual biomarker, a z-score was calculated according to the formula: (individual value - 
population mean)/population standard deviation. The resulting individual biomarker z-
scores were then averaged into an overall standardized sum score for both LGI and ED using 
the same formula. The LGI sum score consisted of the biomarkers CRP, SAA, sICAM-1, IL-6, 
IL-8 and TNF-α; and the ED sum score consisted of the biomarkers sVCAM-1, sICAM-1, sE-
selectin and vWF. sICAM-1 was included in both sum scores, as it is expressed by both 
monocytes and the endothelium (Schram and Stehouwer, 2005). To check whether this 
influenced the results, we also calculated the overall sum scores for inflammation and 
endothelial dysfunction without sICAM-1. 
Linear regression analyses were used to assess the associations between individual 
biomarkers and sum scores of inflammation and endothelial dysfunction with the level of 
depressive symptoms. Logistic regression analyses were used to assess the associations 
between individual biomarkers and sum scores of inflammation and endothelial dysfunction 
with depressive disorder. Due to the relatively low number of depression cases a maximum 
of 6 confounding variables were included in the analyses. Analyses were adjusted for 
covariates in a three way approach: model 1 was the crude model, in model 2 demographic 
variables age and sex were incorporated, and model 3 additionally included the clinical 
variables T2DM, eGFR and history of CVD. To evaluate the effects of lifestyle factors on the 
association of LGI and ED with depression, associations were additionally adjusted for 
smoking, alcohol use and BMI in separate models. A sensitivity analysis was performed for 
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the lifestyle variable physical activity, due to the large number of missing values on this 
variable. A P-value <0.05 was considered to indicate statistical significance in two-sided 
tests.  
The Maastricht Study is characterized by oversampling of T2DM. Therefore, a sensitivity 
analysis was performed to examine whether the associations between LGI, ED and measures 
of depression differed between individuals with and without T2DM. For interaction terms a 
P-value of <0.10 was considered to indicate statistically significant interaction.  
 
Results 
General characteristics 
Table 1 shows the general characteristics of the study population, consisting of 852 
participants (55% men, mean age 60 years), according to diagnosis of depressive disorder. 
Data on biomarkers of ED were available in 831 individuals, data on biomarkers of LGI were 
available in 842 individuals. Missing data on biomarkers were caused by difficulties in blood 
withdrawal. Data on depression for the MINI interview were available in 852 individuals, 
PHQ-9 scores in 757. Missing data on depression scores were mainly due to not completing 
the questionnaires or rejecting the interview. In total, 6.5% (n=55) of the participants had a 
minor or major depressive disorder. These individuals had higher HbA1c levels, were more 
likely to smoke, less likely to be physically active and had higher levels of CRP, SAA, sICAM-1 
and sE-selectin.  
 
Association of LGI with depression 
Table 2 shows crude associations of higher CRP, TNF-α, SAA and sICAM-1 with depressive 
symptoms (regression coefficients (βs) and 95% confidence interval [95%CI]; 0.38 [0.12; 
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0.64], 0.33 [0.06; 0.59], 0.31 [0.05; 0.58] and 0.40 [0.12; 0.68], respectively, in separate 
models), and depressive disorder (odds ratios (ORs) and 95%CI; 1.64 [1.25; 2.15], [1.34 1.03; 
1.75], 1.42 [1.11; 1.82] and 1.35 [1.10; 1.64], respectively). IL-6 and IL-8 were not associated 
with depressive symptoms and depressive disorder. Furthermore, the sum score of LGI was 
statistically significantly associated with depressive symptoms (β 0.46 [0.19; 0.72]) and 
depressive disorder (OR 1.51 [1.19; 1.91]). 
Table 3 shows an association of the sum score of LGI with depressive symptoms and 
depressive disorder after adjustment for age, sex, T2DM, eGFR and prior CVD (β 0.49 [0.21; 
0.77] and OR 1.54 [1.18; 2.02] respectively). Additional adjustment for the lifestyle factors 
smoking, alcohol, and BMI did not materially alter the associations with depressive 
symptoms or depressive disorder. 
 
Association of ED with depression 
Table 4 shows crude associations of higher sICAM-1 and sE-Selectin levels with depressive 
symptoms (β 0.40 [0.12; 0.68] and β 0.26  [0.00; 0.53] respectively) and depressive disorder 
(OR 1.35 [1.10; 1.65] and OR 1.36 [1.11; 1.66] respectively), while sVCAM-1 and vWF were 
not associated with depressive symptoms or depressive disorder. Additionally, the ED sum 
score was statistically significantly associated with depressive symptoms (β 0.35 [0.08; 0.63]) 
and depressive disorder (OR 1.40 [1.14; 1.73]).  
Table 5 shows an association of the sum score of ED with depressive symptoms after 
adjustment for age and sex (β 0.52 [0.24; 0.80]), however, after additional adjustments the 
association estimate weakened, and became non-significant. Furthermore, a statistically 
significant association was found for the sum score of ED with depressive disorder after 
adjustment for age, sex, T2DM, eGFR and prior CVD (OR 1.40 [1.10; 1.77]). Additional 
  
12 
 
adjustment for the lifestyle factors smoking, alcohol and BMI did not materially alter the 
association with depressive disorder.  
 
Sensitivity analyses 
Because the number of missings on the variable “physical activity” was 136 for the total 
sample, and 19 for depressed participants, we adjusted for this lifestyle factor in a sensitivity 
analysis to sustain power in the main analyses. These additional adjustments did not 
materially alter the associations of LGI with depressive symptoms or depressive disorder, nor 
the association of ED with depressive symptoms (data not shown). However, the association 
of ED with depressive disorder weakened after adjustment for physical activity, and became 
non-significant (OR 1.19, 95%CI 0.87; 1.63, p = 0.273), probably due to the reduced statistical 
power of that particular analysis. 
To determine whether the associations between LGI, ED and measures of depression were 
different across T2DM status, an interaction term was added to the regression models. No 
significant interactions were observed (data not shown). In addition, we performed logistic 
regression analyses for minor and major depression separately to see whether there were 
different effect sizes for both measures. Although the number of cases was low, the effect 
sizes of the observed associations were similar (data not shown). 
Furthermore, overall sum scores for LGI and ED were calculated without sICAM-1, to check 
whether this influenced the results. Excluding s-ICAM-1 from the overall sum scores did not 
change the results (data not shown). 
 
Discussion 
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In this study we found that both low grade inflammation and endothelial dysfunction were 
associated with depressive disorder, independent of age, sex, type 2 diabetes status, 
estimated glomerular filtration rate, prior cardiovascular disease and lifestyle factors 
smoking, alcohol consumption and body mass index. The association of low grade 
inflammation with depressive symptoms was independent of lifestyle factors, while the 
association of endothelial dysfunction attenuated by adjustment for smoking, alcohol use 
and body mass index.  
LGI and depression 
We found that higher levels of individual biomarkers CRP and TNF-α were significantly 
associated with depressive symptoms and depressive disorder, while this was also the case 
for markers SAA and sICAM-1. Accordingly, higher levels of the sum score of LGI were 
significantly associated with depressive symptoms and depressive disorder, independent of 
possible covariates.  
Various hypotheses have been proposed as an explanation for the association of 
inflammation with depression. First, inflammation could induces sickness behavior, which is 
closely related to or may induce symptoms of depression. A previous review by Dantzer et al 
(Dantzer et al., 2008) concluded that pro-inflammatory cytokines are able to cause 
depressive disorder, via immune-to-brain communication in which pro-inflammatory 
cytokines cause feelings of depression via different pathways. The first pathway proposed by 
Dantzer et al. is the neural pathway in which locally produced cytokines activate primary 
afferent nerves in the brain during infection (Romeo et al., 2001). The second pathway is the 
humoral pathway, in which Toll-like receptors outside the blood-brain barrier produce pro-
inflammatory cytokines which enter the brain via fluid diffusion (Vitkovic et al., 2000). A 
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third pathway comprises cytokine transporters at the blood-brain barrier; pro-inflammatory 
cytokines overflowing in the systemic circulation can gain access to the brain through these 
transport systems (Banks, 2006). A fourth pathway involves IL-1 receptors that are located 
on endothelial cells of brain venules. Activation of these IL-1 receptors by circulating 
cytokines results in the local production of prostaglandins (Schiltz and Sawchenko, 2002). 
Engagement of these immune-to-brain communication pathways ultimately leads to the 
production of pro-inflammatory cytokines by microglial cells in the brain, which 
consequently can induce symptoms of depression (Dantzer et al., 2008). 
Another potential pathway for the association of inflammation with depression refers to the 
vascular depression hypothesis, which postulates that vascular damage in the brain 
predisposes to depressive symptoms via damage to deep and frontal brain structures that 
are involved in mood regulation (Alexopoulos et al., 1997). As immune dysregulation is 
critically involved in vascular disease (Willerson and Ridker, 2004), and promotes endothelial 
dysfunction, this vascular damage could be the result of increased levels of inflammation. In 
addition, there is evidence suggesting that inflammation can cause HPA-axis hyperactivity by 
disturbing the negative feedback inhibition of circulating corticosteroids on the HPA-axis 
(Schiepers et al., 2005), which in turn is known to be associated with depression, and causes 
hypotrophy in the hypothalamus, hippocampus and pre-frontal cortex (Zunszain et al., 
2011).  
However, when studying the association between inflammation and depression, the effects 
of (adverse) health behaviors / lifestyle factors should also be taken into account. Several 
lifestyle factors are known to relate to depression such as smoking (Luger et al., 2014), 
alcohol intake  (Boden and Fergusson, 2011), and obesity (Luppino et al., 2010), and they 
  
15 
 
also have an influence on low-grade inflammation and endothelial dysfunction. For instance, 
cigarette smoking is known to promote inflammation (McEvoy et al., 2015), possibly via the 
production of reactive oxygen species (ROS).  Observational studies indicate that moderate 
drinkers have lower levels of markers of inflammation, especially CRP, while non-drinkers 
and heavy drinkers have higher CRP concentrations (Imhof et al., 2001). Obesity has also 
been linked to inflammation, as in people with obesity the levels of CRP, IL-6 and TNF-α have 
been demonstrated to be higher compared to people with a normal weight, probably 
through the production of inflammatory markers by adipocytes (Park et al., 2005). It could 
therefore be suggested that lifestyle factors could play an important confounding role in the 
association between inflammation and depression. Nevertheless, in our study inflammation 
remained significantly associated with depressive disorder and depressive symptoms after 
adjustment for smoking, alcohol use and body mass index. 
ED and depression 
Our results showed that higher levels of sICAM-1 and sE-selectin were significantly 
associated with a higher levels of depressive symptoms and greater risk of depressive 
disorder. Higher levels of the sum score of ED were associated with higher levels of 
depressive symptoms, however, after adjustment for clinical and lifestyle variables this 
association became non-significant. In addition, higher levels of the sum score of ED was 
significantly associated with depressive disorder, independent of possible covariates. 
A growing body of literature has linked endothelial dysfunction with depression (Hemingway 
et al., 2003; Lesperance et al., 2004). The association seems to be graded and linear, such 
that even minor increases in depressive symptoms are joined with decreased endothelial 
function (Lavoie et al., 2010; Tomfohr et al., 2008). For example, a meta-analyses of twelve 
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studies (Cooper et al., 2011) showed an association between diminished flow mediated 
vasodilation (FMD), a functional marker of endothelial dysfunction, and depression. 
Nonetheless, the question can be raised whether biomarkers of ED and FMD represent the 
same phenomenon. However, a recent study of our group (van Sloten et al., 2014) used both 
plasma biomarkers and FMD to measure ED, and showed an independent association of ED 
with depressive symptoms, confirming our results in a different population. Nevertheless, 
this study (van Sloten et al., 2013) used a self-report questionnaire for the assessment of 
depression whereas we additionally used a diagnostic interview, which is the gold standard 
for the assessment of depression.  
The underlying mechanisms linking concurrent depression and endothelial function in 
prospective studies remain unclear; however, several biological mechanisms have been 
proposed. For example, depressive mood was associated with dysregulation of the 
autonomic nervous system and HPA-axis (Goldston and Baillie, 2008), both of which are 
associated with ED (Harris and Matthews, 2004). It has also been suggested that ED may lead 
to depression via the development of cardiovascular disease, as ED is a key factor  in its 
pathophysiology (Aird, 2007), and depression is common in people with CVD (Belmaker and 
Agam, 2008). Nonetheless, when we adjusted for prior CVD and T2DM, a CVD risk factor, the 
association between ED and depressive disorder remained significant, suggesting that this 
association is independent of CVD.  
Lifestyle factors may also play an important confounding role in the association between ED 
and depression. All lifestyle factors implemented in our model are known to be associated 
with both depression (Boden and Fergusson, 2011; Luger et al., 2014; Luppino et al., 2010) 
and ED.  For instance, cigarette smoking has long been known to produce reactive oxygen 
species (ROS) (Church and Pryor, 1985), which damage the endothelium, thereby causing a 
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reduction in nitric oxide bioavailability and, thus endothelial dysfunction (Kiowski et al., 
1994). In contrast, moderate alcohol consumption was found to be associated with 
improved endothelial function (Teragawa et al., 2002), whereas obesity has been associated 
with deteriorating endothelial function (Iantorno et al., 2014). However, the association of 
ED with depressive disorder remained significant after adjustment for lifestyle variables. The 
association of ED with depressive symptoms attenuated after adjustment for type 2 
diabetes, kidney function, prior CVD, and even more after adjusting for smoking, alcohol use 
and BMI. Therefore, these lifestyle factors can only partly explain the association of ED with 
depressive symptoms. 
As expected, the association of both LGI and ED with depression appeared to be stronger for 
depressive disorder than for depressive symptoms. This is in accordance with a meta-
analysis of Howren et al. (Howren et al., 2009), which demonstrated stronger effects 
between plasma biomarkers and depression for studies using diagnostic interviews as 
compared self-report questionnaires. Together with the fact that our results were adjusted 
for possible confounding or mediating factors, our results seem to suggest a true 
relationship of inflammation and ED with clinically relevant depression.  
A limitation of this study is its cross-sectional design. Therefore, we cannot draw any 
conclusions regarding the causality of the association, as inflammation and endothelial 
dysfunction could both be a cause or a result of having depression. Another limitation is the 
loss of power in statistical analyses, due to missings on several variables. Moreover, we do 
not have any data on the use of antidepressants or other antidepressant treatment available 
yet, which could potentially have influenced the results.Strengths of our study include the 
use of both a diagnostic interview and self-report to assess depression, and the wide range 
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of biomarkers that we used to measure inflammation and endothelial dysfunction. All the 
LGI markers (CRP, SAA, sICAM-1, IL-6, IL-8 and TNF-α) are involved in the inflammatory 
process (Ross, 1999) and all the markers of ED (sVCAM-1, sICAM-1, sE-selectin and vWF) are 
known to be synthesized by endothelial cells (Schram and Stehouwer, 2005; Vischer, 2006). 
Therefore, it is valid to assume that higher circulating concentrations of these markers 
reflect more inflammatory activity or dysfunction of the endothelium, respectively.  
Conclusions 
Low grade inflammation and endothelial dysfunction were positively associated with 
depressive disorder, and levels of depressive symptoms. Except for the association between 
endothelial dysfunction and depressive symptoms, these associations were independent of 
clinical and lifestyle variables. These results suggest that low grade inflammation and 
endothelial dysfunction are associated with depression, and that lifestyle factors can only 
partly explain these associations.  
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Table 1. General characteristics of The Maastricht Study participants  
 
 Total population (n=852) Depressive disorder (n=852;  MINI) 
 
 
  No (n=797) Yes (n=55) 
 
p-value 
Male sex (n) 
 
55% (467) 
 
55% (438) 
 
53% (29) 
 
0.748 a 
Age, years 
 
59.8 ± 8.5 59.8 ± 8.5 59.0 ± 8.9 0.463 
b
 
Having a partner  (n) 
 
85% (715) 86% (673) 76% (42) 0.063 
a
 
Type 2 diabetes (n) 
 
29% (251) 29% (229) 40% (22) 0.076 
a
 
Diabetes duration, years 
 
8.4 ± 6.9 8.1 ± 6.9 10.4 ± 6.7 0.176 
b
 
HbA1c, % 
 
6.0 ± 0.8 6.0 ± 0.8 6.4 ± 1.2 0.042
 c
 
Fasting glucose level, mmol/L 
 
6.1 ± 1.5 6.1 ± 1.4 6.6 ± 2.6 0.140
 c
 
Smoking;  
never / former / current (%) 
31%/ 53% / 16% 32% / 53% / 15%  19% / 51% / 30% 0.009 
a
 
Alcohol consumption;  
no / low / high (%) 
17% / 53% / 30%  17% / 53% / 30%  
 
24% / 49% / 27%  
 
0.511 
a
 
 
BMI, kg/m
2
  
 
27.4 ± 4.5 27.3 ± 4.5 28.2 ± 5.1 0.184 
b
 
Waist circumference, cm 
 
97.2 ± 13.6 97.0 ± 13.4 99.6 ± 15.8 0.175 
b
 
Waist-to-hip ratio 
 
0.95 ± 0.09 0.95 ± 0.09 0.96 ± 0.10 0.266 
b
 
Physical activity 
 
14.3 ± 8.0 14.5 ± 8.2 11.5 ± 4.8) 0.001 
b
 
Systolic blood pressure, mmHg 
 
137.4 ± 19.0 137.1 ± 18.9 141.0 ± 20.4 0.141 
b
 
Diastolic blood pressure, mmHg 
 
76.7 ± 10.3 76.7 ± 10.2 77.5 ± 12.3 0.544 
b
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Anti-hypertensive medication  
 
40%  (342) 40% (316) 47% (26) 0.265 
a
 
Total cholesterol, mmol/L 
 
5.2 ± 1.2 5.2 ± 1.2 5.2 ± 1.2 0.991 
b
 
Total-to-HDL cholesterol ratio 
 
4.5 ± 8.6 4.5 ± 8.8 
 
4.5 ± 1.5 0.970 
b
 
 
Lipid-modifying medication  
 
37% (315) 37% (292) 42% (23) 0.441 
a
 
History of CVD  
 
18% (147) 18% (139) 15% (8) 0.610 
a
 
Estimated GFR,  ml/min/1.73m2 
 
84.7 ± 14.6 84.7 ± 14.7 84.7 ± 13.6 0.998 
b
 
C-reactive protein (µg/ml) 
Median (interquartile range) 
1.19 ± 2.2 1.15 ±  2.1 2.07 ±  2.8 <0.001
 d
 
Serum amyloid A (µg/ml) 
Median (interquartile range) 
2.77 ± 3.4  2.74 ±  3.2  4.28 ±  6.5 0.005
 d
 
sICAM-1 (ng/ml) 
 
258.5 ± 68.1 256.7 ±  67.4 284.9 ±  71.9 0.003
 b
 
Interleukin-6 (pg/ml) 
Median (interquartile range) 
1.43 ± 1.2 1.42 ±  1.14 1.68 ±  1.36 0.078
 d
 
Interleukin-8 (pg/ml) 
Median (interquartile range) 
3.76 ± 1.7 3.75 ±  1.7 4.02 ±  2.4 0.309
 d
 
Tumor necrosis factor alpha (pg/ml) 
Median (interquartile range) 
2.53 ± 1.0 2.52 ±  1.0 2.68 ±  1.3 0.058
 d
 
sVCAM-1 (ng/ml) 
 
404.1 ± 101.0 402.4 ± 101.0 428.5 ±  99.3 0.064
 b
 
sE-Selectin (ng/ml) 
 
13.4 ± 7.6 13.2 ±  7.4 16.5 ± 10.3 0.002
 b
 
Von Willebrand factor (%) 
 
134.9 ± 47.6 134.3 ± 47.8 143.1 ± 44.8 0.187
 b
 
Total score on PHQ-9  
 
2.7 ± 3.6 2.2 ± 2.6 10.6 ± 6.8 <0.001 
d
 
Data are presented as mean ± standard deviation unless otherwise indicated. 
a
 = Chi-square  
b
 = Independent Samples T-Test   
c
 = T-Test, equal variances not assumed   
d
 = Mann Whitney-U   
HbA1c = hemoglobin A1c, BMI = body mass index, HDL = High-density lipoprotein, CVD = cardiovascular disease, GFR = glomerular filtration rate 
sICAM-1 = soluble intercellular adhesion molecule-1, sVCAM-1 = soluble vascular cell adhesion molecule-1, PHQ-9 = Patient Health Questionnaire 9 items  
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Table 2: Univariate associations of individual biomarkers and the sum score of low-grade inflammation with measures of depression 
 
 
 
Independent  
variable 
 
 
 
Depressive symptoms    
 
 Depressive disorder 
(n = 55)  
 
  
B 
 
   95% CI 
 
p-value 
 
OR 
 
95% CI 
 
p-value 
CRP * 0.38 
 
0.12; 0.64 0.004 1.64 1.25; 2.15 <0.001 
TNF-α * 
 
0.33 0.06; 0.59 0.017 1.34 1.03; 1.75 0.032 
SAA * 0.31 
 
0.05; 0.58 0.021 1.42 1.11; 1.82 
 
0.005 
sICAM-1  
 
IL-6 * 
 
IL-8 * 
 
LGI sum score 
 
0.40 
 
0.18 
 
0.18 
 
0.46 
0.12; 0.68 
 
-0.08; 0.44 
 
-0.09; 0.44 
 
0.19; 0.72 
0.006 
 
0.170 
 
0.196 
 
0.001 
1.35 
 
1.13 
 
1.13 
 
1.51 
1.10; 1.65 
 
0.90; 1.43 
 
0.90; 1.44 
 
1.19; 1.91 
0.004 
 
0.290 
 
0.297 
 
0.001 
 
Independent variables reflect Z-scores  
* variables were log-transformed prior to standardization. 
 
CRP = C-reactive protein, TNF-α = tumor necrosis factor alpha, SAA = serum amyloid A, sICAM-1 = soluble intercellular adhesion molecule-1,  
IL-6 = interleukin-6, IL-8 = interleukin-8, LGI = low-grade inflammation  
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Table 3: Associations of the sum score of low-grade inflammation with depressive symptoms and depressive disorder 
 
 
Independent  
variable 
 
 
 
Depressive symptoms  
 
N included in 
analysis 
 
     Depressive disorder   
 
 
 N included in 
analysis 
 
  
B 
 
95% CI 
 
p-value 
  
OR 
 
95% CI 
 
p-value 
no 
depression/ 
depression 
Model 1: crude 
 
0.46 0.19; 0.72 0.001 731 1.51 1.19; 1.91 0.001 778/55 
Model 2: adjusted 
for age, sex 
 
0.66 0.38; 0.93 <0.001 731 1.61 1.26; 2.06 <0.001 778/55 
Model 3: model 2 + 
T2DM, eGFR, prior 
CVD 
 
0.49 0.21; 0.77 0.001 709 1.54 1.18; 2.02 0.001 744/52 
Model 4: model 3 + 
smoking 
 
0.37 0.09; 0.65 0.009 706 1.43 1.09; 1.88 0.011 742/51 
Model 5: model 3 + 
alcohol consumption 
 
0.47 0.19; 0.76 0.001 704 1.54 1.17; 2.03 0.002 740/50 
Model 6: model 3 + 
body mass index 
 
0.32 0.01; 0.62 0.042 708 1.56 1.17; 2.08 0.002 743/52 
 
Independent variables reflect Z-scores 
T2DM = type 2 diabetes, eGFR = estimated glomerular filtration rate, CVD = cardiovascular disease   
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Table 4: Univariate associations of individual biomarkers and the sum score of endothelial dysfunction with measures of depression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Independent variables reflect Z-scores 
 
sVCAM-1 = soluble vascular cell adhesion molecule-1, sICAM-1 = soluble intercellular adhesion molecule-1, vWF = Von Willebrand factor,  
ED = endothelial dysfunction  
 
  
 
Independent  
Variable 
 
 
 
Depressive symptoms  
 
  
 
  
 
 
Depressive disorder 
(n = 55) 
  
B 
 
   95% CI 
 
p-value 
 
OR 
 
95% CI 
 
p-value 
sVCAM-1  0.23 
 
-0.03; 0.50 0.083 1.25 0.99; 1.58 
 
0.065 
sICAM-1  0.40 
 
0.12; 0.68 0.006 1.35 1.10; 1.65 0.004 
sE-Selectin 
 
vWF 
 
ED sum score 
 
0.26 
 
0.10 
 
0.35 
0.00; 0.53 
 
-0.17; 0.36 
 
0.08; 0.63 
0.050 
 
0.472 
 
0.012 
  1.36 
 
1.19 
 
1.40 
1.11; 1.66 
 
0.92; 1.53 
 
1.14; 1.73 
0.003 
 
0.188 
 
0.001 
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Table 5: Associations of the sum score of endothelial dysfunction with depressive symptoms and depressive disorder  
 
 
Independent  
variable 
 
 
 
Depressive symptoms  
 
N included in 
analysis 
 
     Depressive disorder   
 
 
 N included in 
analysis 
 
  
B 
 
95% CI 
 
p-value 
  
OR 
 
95% CI 
 
p-value 
no 
depression/ 
depression 
Model 1: crude 
 
0.35 0.08; 0.63 0.012 720 1.40 1.14; 1.73 0.001 767/55 
Model 2: adjusted 
for age, sex 
 
0.52 0.24; 0.80 <0.001 720 1.47 1.18; 1.82 <0.001 767/55 
Model 3: model 2 + 
T2DM, eGFR, prior 
CVD 
 
0.28 -0.01; 0.57 0.060 698 1.40 1.10; 1.77 0.006 733/52 
Model 4: model 3 + 
smoking 
 
0.20 -0.09; 0.48 0.173 695 1.34 1.05; 1.70 0.020 731/51 
Model 5: model 3 + 
alcohol consumption 
 
0.24 -0.06; 0.53 0.116 693 1.37 1.07; 1.75 0.013 729/50 
Model 6: model 3 + 
body mass index 
 
0.12 -0.18; 0.43 0.426 697 1.39 1.08; 1.79 0.010 732/52 
 
Independent variables reflect Z-scores 
T2DM = type 2 diabetes, eGFR = estimated glomerular filtration rate, CVD = cardiovascular disease 
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Highlights 
• hsCRP, TNF-α, SAA, sICAM-1, sE-Selectin were univariate associated with depression  
• sum score of inflammation was associated with depression, also after adjustments  
• sum score of endothelial dysfunction was associated with depressive disorder 
• sum score of endothelial dysfunction was not associated with depressive symptoms 
 
 
 
 
